Jesus-Silva, Jorge A. http://orcid.org/0000-0001-9694-2323
Lamplugh, Archie
Dhada, Sameera
Burton, James O.
Bhandari, Sunil
Article History
Received: 8 December 2019
Accepted: 25 May 2020
First Online: 3 June 2020
Ethics approval and consent to participate
: The study was part of service improvement in the implementation and assessment of a change in therapy and was registered (Project Number 10351) with the University Hospitals of Leicester NHS Trust Clinical Audit, Standards and Effectiveness (CASE) Team who provided permission and support for the use of anonymised patient records to assess the impact of the intervention. This study was also given a favourable opinion from the Hull University Teaching Hospitals NHS Trust Research and Development Committee who provided approval for the use of anonymised patient data for the potential benefit of service and patient care. All the principles of the declaration of Helsinki and the ICH and good governance were followed and data anonymity was maintained throughout.
: All authors read and approved the final manuscript for publication.
: The results presented in this paper have not been published previously in whole or part, except in abstract format. Dr. Jorge Jesus-Silva has received funding from Pharmacosmos to attend and present a poster in abstract at the American Society of Nephrology conference. Professor James Burton has received honoraria for lectures, attended expert opinion committees and received sponsorship to attend congresses from Pharmacosmos, Vifor Pharma, NAPP and Bristol-Myers Squibb. Professor Sunil Bhandari has received honoraria for lectures, attended expert opinion committees, and received educational funds to attend the European Renal Association-European Dialysis and Transplant Association from Pharmacosmos and Vifor Pharma. Mr. Archie Lamplugh, Sameera Dhada and Beverly Pearce have no conflicts of interest.